Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers.
Kuchinski K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2024
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
The variation landscape of CYP2D6 in a multi-ethnic Asian population.
Maulana Y et al.
Scientific Reports, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics.
Stern S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O
Nucleosides, Nucleotides & Nucleic Acids, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
A Computational Understanding of Inter-Individual Variability in CYP2D6 Activity to Investigate the Impact of Missense Mutations on Ochratoxin A Metabolism.
Dorne JLCM et al.
Toxins, 2022
Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Dong AN et al.
Drug Metabolism and Bioanalysis Letters, 2022
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).
Low JL et al.
Ebiomedicine, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Benchmarking analysis of deleterious SNP prediction tools on CYP2D6 enzyme.
Ferreira KCDV et al.
Chemical Biology & Drug Design, 2020
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH et al.
Clinical Pharmacology and Therapeutics, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population.
Nguyen HH et al.
Medicine, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.
Goh LL et al.
Plos One, 2017
Comparison of genome sequencing and clinical genotyping for pharmacogenes.
Yang W et al.
Clinical Pharmacology and Therapeutics, 2016
Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
Borba MA et al.
Pharmacogenomics, 2016
Molecular Dynamics Simulations to Investigate the Influences of Amino Acid Mutations on Protein Three-Dimensional Structures of Cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62.
Fukuyoshi S et al.
Plos One, 2016
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX et al.
Drug Metabolism Reviews, 2015
High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians.
Al-Dosari MS et al.
Environmental Toxicology and Pharmacology, 2013
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.
Ruaño G et al.
Biomarkers in Medicine, 2013
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
Teh LK et al.
Drug Metabolism and Pharmacokinetics, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B et al.
Drug Metabolism Reviews, 2009
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clinical Pharmacokinetics, 2009
Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008
Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population.
Cai WM et al.
Clinical Pharmacology and Therapeutics, 2007
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2004
Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells.
Shiraishi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Nikoloff D et al.
The Pharmacogenomics Journal, 2002
Genetic polymorphism of human cytochrome p450 involved in drug metabolism.
Nagata K et al.
Drug Metabolism and Pharmacokinetics, 2002
Pharmacogenetics in the practice of laboratory medicine.
Linder MW et al.
Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology, 1999
G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 1999
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW et al.
Critical Reviews in Toxicology, 1999